Ana C. González-Baró

Bio: Ana C. González-Baró is an academic researcher from National University of La Plata. The author has contributed to research in topics: Crystal structure & Oxalate. The author has an hindex of 15, co-authored 51 publications receiving 710 citations. Previous affiliations of Ana C. González-Baró include University of Burgos & National Scientific and Technical Research Council.

Spectroscopic investigations of iron(II) and iron(III) oxalates

Abstract: In an attempt to contribute to a better characterization of FeII and FeIII oxalate complexes, an investigation of their vibrational (infrared and Raman) and 57Fe-Mossbauer spectra was performed. It is shown that the two polymorphs, α and β, of FeC2O4•2H2O cannot be accurately differentiated with any of these spectroscopic methods, demonstrating the high structural similarity of these two crystalline forms. Partially deuterated samples of β-FeC2O4•2H2O were also investigated to improve the vibrational-spectroscopic analysis. In the case of Fe2(C2O4)3•4H2O, a structural model, derived from results of combined vibrational and Mossbauer data, could be proposed. The 298 K Mossbauer spectrum for this complex is discussed in detail for the first time.

Antitumour metal compounds: more than theme and variations

Abstract: Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment of colon cancer should, however, not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs. Strategies opening up new avenues are increasingly being sought using complexes of metals other than platinum such as ruthenium or gallium. Based on the chemical differences between these metals, the spectrum of molecular mechanisms of action and potential indications can be broadened substantially. Other approaches focus on complexes with tumour-targeting properties, thereby maximizing the impact on cancer cells and minimizing the problem of adverse side effects, and complexes with biologically active ligands.

Chlorogenic Acid: Recent Advances on Its Dual Role as a Food Additive and a Nutraceutical against Metabolic Syndrome.

Abstract: Chlorogenic acid (5-O-caffeoylquinic acid) is a phenolic compound from thehydroxycinnamic acid family. This polyphenol possesses many health-promoting properties, mostof them related to the treatment of metabolic syndrome, including anti-oxidant, anti-inflammatory,antilipidemic, antidiabetic, and antihypertensive activities. The first part of this review will discussthe role of chlorogenic acid as a nutraceutical for the prevention and treatment of metabolicsyndrome and associated disorders, including in vivo studies, clinical trials, and mechanisms ofaction. The second part of the review will be dealing with the role of chlorogenic acid as a foodadditive. Chlorogenic acid has shown antimicrobial activity against a wide range of organisms,including bacteria, yeasts, molds, viruses, and amoebas. These antimicrobial properties can beuseful for the food industry in its constant search for new and natural molecules for thepreservation of food products. In addition, chlorogenic acid has antioxidant activity, particularlyagainst lipid oxidation; protective properties against degradation of other bioactive compoundspresent in food, and prebiotic activity. The combination of these properties makes chlorogenic acidan excellent candidate for the formulation of dietary supplements and functional foods.